Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
8,992,499
-
Shares change
-
-1,001,680
-
Total reported value, excl. options
-
$272,944,664
-
Value change
-
-$29,352,795
-
Put/Call ratio
-
100%
-
Number of buys
-
57
-
Number of sells
-
-40
-
Price
-
$30.35
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2021
126 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2021.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,992,499 shares
.
Largest 10 shareholders include Artemis Investment Management LLP (1,380,260 shares), STATE STREET CORP (1,328,599 shares), BlackRock Inc. (1,216,737 shares), ALLIANCEBERNSTEIN L.P. (1,020,255 shares), VANGUARD GROUP INC (967,920 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (417,510 shares), GEODE CAPITAL MANAGEMENT, LLC (297,039 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (239,224 shares), UBS Group AG (215,725 shares), and NORTHERN TRUST CORP (190,098 shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.